| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 442.99% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 08/08/2023 | 442.99% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 05/04/2023 | 442.99% | HC Wainwright & Co. | → $12 | Reiterates | → Buy |
| 03/20/2023 | 442.99% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 03/08/2023 | 578.73% | HC Wainwright & Co. | → $15 | Reiterates | → Overweight |
| 02/08/2023 | 578.73% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 01/31/2022 | 578.73% | HC Wainwright & Co. | → $15 | Assumes | → Buy |
| 10/19/2021 | 623.98% | Maxim Group | → $16 | Upgrades | Hold → Buy |
What is the target price for Indaptus Therapeutics (INDP)?
The latest price target for Indaptus Therapeutics (NASDAQ: INDP) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $12.00 expecting INDP to rise to within 12 months (a possible 442.99% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Indaptus Therapeutics (INDP)?
The latest analyst rating for Indaptus Therapeutics (NASDAQ: INDP) was provided by HC Wainwright & Co., and Indaptus Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Indaptus Therapeutics (INDP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Indaptus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Indaptus Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating Indaptus Therapeutics (INDP) correct?
While ratings are subjective and will change, the latest Indaptus Therapeutics (INDP) rating was a reiterated with a price target of $0.00 to $12.00. The current price Indaptus Therapeutics (INDP) is trading at is $2.21, which is within the analyst's predicted range.
